News List

Lupin ties up with Nichi-Iko to sell biosimilar drug in Japan


Lupin and Japan’s Nichi-Iko have entered into a pact for the distribution, promotion and sale of Lupin\'s biosimilar drug Etanercept in Japan.

By Team ABLE

Pharmaceutical companies Lupin and Japan’s Nichi-Iko have entered into a pact for the distribution, promotion and sale of Lupin\'s biosimilar drug Etanercept in Japan.
The drug is used for treatment of rheumatoid arthritis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and polyarticular juvenile idiopathic arthritis.

Developed by YL Biologics, a joint venture between the company\'s arm Lupin Atlantis Holdings SA and Yoshindo, the product will be launched by Japan\'s Nichi-Iko after receiving approval from the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan, Lupin said in a filing to BSE.

Lupin\'s subsidiary, Kyowa had submitted a New Drug Application (NDA) for marketing authorisation to the PMDA in March this year following the successful conclusion of its global phase III study, it added.